A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients

The combination of sequential azacitidine and midostaurin is safe and tolerable with response rates comparable with azacitidine alone and should be studied further in FLT3 mutation-positive AML.